Medical device based on 3% Boric Acid for the treatment of vaginal infections and dryness: results after 4 weeks of treatment
Vaginal infections, particularly those caused by Candida albicans, represent one of the main causes of intimate discomfort in women, with recurrent episodes that significantly affect daily well-being and quality of life.
To meet this clinical need, Gruppo FarmaImpresa has developed Lattawin Gel 3%, a medical device in gel form based on 3% Boric Acid, combined with selected natural active ingredients for a targeted yet gentle action.
Clinical study on Candida: results after 2 weeks
A clinical study was conducted on 30 patients with a vaginal swab positive for Candida albicans.
The results were extremely encouraging: after just two weeks of treatment, 90% of the women achieved swab negativization.
Positivity, initially present in 100% of patients, dropped drastically to 3.6%, with clinically and statistically significant results (p<0.0001).
These findings confirm the antifungal effectiveness of our gel, which works by rebalancing the vaginal microbiota and actively combating Candida proliferation, offering a valuable alternative to conventional treatments.
Vaginal dryness: a symptom not to be underestimated
In addition to its effectiveness against infections, Lattawin Gel 3% has proven to be a valuable ally in the treatment of vaginal dryness, a condition particularly common in postmenopausal women but still often overlooked.
Characterized by symptoms such as itching, burning, irritation, and pain during intercourse, vaginal dryness can deeply impact a woman’s emotional, social, and sexual well-being.
Clinical study on dryness: improvements already in 4 weeks
To assess the benefits of our gel on dryness, a second clinical study was conducted on 20 patients using the Vulvovaginal Symptoms Questionnaire (VSQ), a validated tool for measuring symptom severity and its impact on quality of life.
After four weeks of daily treatment, 95% of women reported total remission of dryness-associated symptoms.
The average questionnaire score dropped from 4.10 to 0.15, indicating a significant and clinically relevant reduction (p<0.001).
Figure 1 shows the overall reduction in the 16-item VSQ scores from baseline (T0) to after treatment (T1).
In particular, itching disappeared in 95% of cases, vaginal dryness was significantly reduced (from 85% to 40%), and all cases of abnormal vaginal discharge and bad odor resolved.
Beyond physical improvements, patients reported marked enhancement in emotional and relational well-being, demonstrating how adequate management of vaginal dryness can restore serenity and confidence even in personal and intimate life.
Positive impact on sexual health
Among the most significant findings of the study, a positive impact on sexuality emerged: the number of women reporting pain, dryness, or bleeding during intercourse more than halved.
The average score relating to sexual quality of life decreased from 7.67 to 1.00, a highly significant difference, indicating a substantial improvement in intimate comfort and satisfaction.
A natural formulation for comprehensive action
The product’s effectiveness is attributed to the synergy between:
- Boric Acid, which provides antifungal action and restores vaginal pH,
- Lactic Acid, essential for maintaining a balanced vaginal microbiota,
- Aloe Vera, Chamomile, Lavender, and Calendula, offering soothing and regenerative effects,
- Hyaluronic Acid and D-Panthenol, ensuring deep hydration and promoting tissue regeneration.
These natural actives work together to offer an effective and gentle solution, even in cases of particularly sensitive mucosa or recurrent infections.
Thanks to the clinical data collected, Lattawin Gel 3% confirms itself as an innovative, safe, and highly effective solution for the treatment of both vaginal infections and dryness.
The medical device, CE certified (under MDR EU 2017/745 regulation, MDD transitional extension), is also available for private label or out-licensing, offering commercial partners a concrete growth opportunity in a rapidly expanding market.
If you are interested in becoming a distributor of our CE-certified 3% Boric Acid-based medical device (under the transitional extension period of the MDR (EU) 2017/745), we are ready to support your growth with tailored solutions for your market.
